In subgroup analysis, Figure 7b shows significant differences in I-FABP levels between the healthy controls and the lean (p = 0.005) and obese I (p = 0.027) subgroups, but there was no significant difference in the biomarker level between healthy controls and the other subgroups of NAFLD. This evidence concerns the gene FABP2 and metabolic dysfunction-associated steatotic liver disease.